Navigation Links
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
Date:5/8/2009

million, or $0.76 per share, for the nine months ended March 31, 2008.

Cash, cash equivalents and investments were $28.8 million at March 31, 2009. The cash and total investments balance included cash, cash equivalents and short-term investments of $21.6 million and long-term auction-rate securities carried at an estimated value of $7.2 million and classified as long-term investments. Total liabilities, excluding deferred revenue of $14.7 million and a warrant liability of $0.2 million, were $6.4 million at March 31, 2009.

"During the third quarter of fiscal 2009, we wound-down most of our operations and significantly reduced expenses. We also initiated a process to identify and evaluate alternatives for the Company's future. Our board's stated mandate in looking at these strategic alternatives is to maximize the value of our cash and other assets for the benefit of all our shareholders, and to proceed expeditiously in the process," stated William Fletcher, acting Chief Executive Officer.

Assuming accrued costs associated with the Viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash, short-term and long-term investments.

-Tables to follow -

About Neurobiological Technologies, Inc.

Neurobiological Technologies, Inc. is a biopharmaceutical company historically focused on developing investigational drugs for central nervous system conditions. The company recently terminated development of its most advanced product candidate, Viprinex(TM) (ancrod), which was studied in Phase 3 clinical trials as a potential new drug to treat acute ischemic stroke. NTI has more recently chosen not to extend its early-stage research programs for Huntington's and Alzheimer's diseases. NTI has rights to receive payments from an approved drug for Alzheimer's disease and an invest
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Neurobiological Technologies Announces Appointment of William A. Fletcher as Acting CEO
2. Neurobiological Technologies Reports Second Quarter Financial Results
3. Dr. Warren Wasiewski Appointed Chief Medical Officer of Neurobiological Technologies, Inc.
4. Neurobiological Technologies Announces Compliance With Nasdaq Listing Standards
5. Neurobiological Technologies Reports $2.1 Million Quarterly Payment for Sales of Memantine
6. Neurobiological Technologies, Inc. Announces Receipt of Determination Letter from NASDAQ
7. Neurobiological Technologies Reports Going Concern Qualification
8. Steven H. Kane Appointed as President and Chief Executive Officer of Patient Safety Technologies, Inc.
9. Global Med Technologies(R), Inc. to Report First Quarter Financial Results on Friday, May 15, 2009
10. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
11. Greenway Medical Technologies PrimeSuite Solution Provides OB/GYN Physicians With Instant Access to Labor and Delivery Information at Point-of-Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... (PRWEB) March 26, 2015 Behavioral ... consulting firm, announced the release of BathroomMap® , ... to increase access to public restrooms for travelers, especially ... bathroom apps, BathroomMap does not facilitate a paid, social ... to identify and rate local establishments that have clean, ...
(Date:3/26/2015)... March 26, 2015 Saving Moses is ... it is most needed but least available. As one ... to six clinics in the Benguela province of Angola ... During a recent visit to their clinics, staff employed ... mothers and their babies in a nation the The ...
(Date:3/26/2015)... March 26, 2015 The Life ... “Introduction to Hyperbaric Medicine” course, which is accredited ... (UHMS) and the National Board of Diving & ... 40-hour course 4 times a year at several ... NY tri-state region; registration is available on-line at: ...
(Date:3/26/2015)... March 26, 2015 BioPlus ... leading innovative specialty pharmacies, announces the promotion of ... Vice President of Pharmaceutical Relations. In this position, ... with our pharmaceuticals partners and providing key leadership ... of BioPlus’ expansion. , “Over the past ...
(Date:3/26/2015)... Md. (PRWEB) March 26, 2015 ... supports the Patients’ Access to Treatments Act (PATA) ... this week by Reps. David B. McKinley (R-WV) ... will limit cost-sharing requirements for medications placed in ... accessible by reducing patients’ out-of-pocket expenses. , This ...
Breaking Medicine News(10 mins):Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 2Health News:New Bathroom Finder App, BathroomMap®, Helps People with Medical Needs Who Urgently Need a Bathroom When Traveling 3Health News:Saving Moses Utilized Photography in an Effort to Engage Mothers and Their Babies on a Recent Visit to Angola 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:BioPlus Specialty Pharmacy Expands Executive Team with New Position, Naming Sharon Ferrer as Vice President of Pharmaceutical Relations 2Health News:Pulmonary Hypertension Association Part of Coalition Supporting the Patients’ Access to Treatments Act 2
... Magazine for a poll it was astonishing that Britons were ... 50% of them said that they believe in possessing mind-reading ... 43% said that they could read others' thoughts or had ... they had dreamt of an event before it occurred, 26% ...
... Researcher Linda Mansfield Michigan State University is a part ... at the role of parasitic worms// in treatment of ... of a more than $10 million National Institutes of ... Research Network of laboratories launched by the National Institutes ...
... Scientists in Japan have developed robotic hands, which they ... ,The artificial hands, developed by Yukiyasu Kamitani and ... based on real-time functional magnetic resonance imaging (fMRI) of ... Scientist. ,Researchers from the ATR Computational Neuroscience ...
... Hospital was suspended a she removed the properly functioning kidney ... found him guilty and suspended him for a period of ... that the French surgeon, Mr Blanchard’s conduct was inappropriate, unprofessional ... ,He said that he had not read the ...
... services in various hospitals affiliated to GSVM medical college ... against the OBC quota in elite educational institutions entered ... and students were continuing with the protest against Centre's ... in higher centres of learning, representatives of agitating doctors ...
... that milk chocolate containing caffeine has been good for ... times. ,Hence, chocolate lovers were found ... ,Adding value to the above study, an under graduate ... Raudenbush, Wheeling Jesuit University has done recently a research, ...
Cached Medicine News:Health News:Parasitic Worms Could Be Used To Treat Bowel Disease 2
(Date:3/26/2015)... VEGAS , March 26, 2015 Zimmer ... Vivacit-E ® Advanced Bearing Technology with ... A paper published earlier this month reported that, ... Vivacit-E Advanced Bearing Technology featuring Vitamin E ... maintained a significant wear rate reduction of 95 percent, ...
(Date:3/26/2015)... WASHINGTON , March 26, 2015 Even ... anniversary of the Food and Drug Administration,s landmark approval ... from 11 members of Congress calling on the Agency ... approving a first-ever medical treatment for women,s most common ... 26 FDA-approved medical treatment options for sexual dysfunction – ...
(Date:3/26/2015)... , March 26, 2015 ... and Drug Safety Software Market by Functionality (Adverse Event ... based (SAAS)), End-user (Pharma & Biotech Companies, CROs, ... MarketsandMarkets, the Pharmacovigilance and Drug Safety Software Market ... 6.5% during 2014-2019, and is expected to reach ...
Breaking Medicine Technology:Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 2Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 2Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 3Even The Score Marks 17th Viagra Anniversary with Release of New Letter from Members of Congress to FDA Calling for Equity in Sexual Health 4Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 2Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 3Pharmacovigilance and Drug Safety Software Market Worth $154.1 Million by 2019 4
... a corporate mission of saving 100,000 more lives each year, ... leading manufacturer of medical devices and software for treating cancer ... expand its corporate branding efforts by tapping advertising agency DeVito/Verdi ... will be handled by the New York City-based agency,s San ...
... May 9, 2011 NxStage Medical, Inc. (Nasdaq: ... innovative dialysis products, today expressed its support for ... educate U.S. Congressional policymakers and their advisors about ... hemodialysis. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO) On ...
Cached Medicine Technology:Leading Medical Device and Software Manufacturer Looks to Build Its Brand With DeVito/Verdi 2Leading Medical Device and Software Manufacturer Looks to Build Its Brand With DeVito/Verdi 3NxStage® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis 2
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... assay method for the semi-quantitative determination ... in human serum. The results of ... as an aid in the diagnosis ... associated with elevated anti-neutrophil cytoplasmic antibodies ...
... The determination of Ang II ... monitoring the pharmacological effect and ... of angiotensin converting enzyme inhibitors ... receptor antagonists as well as ...
... antigen test is a visual ... presumptive qualitative detection of Respitory ... specimens in neonatal and pediatric ... test has a built-in procedural ...
Medicine Products: